Celltrion announced on Jan. 2 that it has completed the transfer of Eli Lilly’s biopharmaceutical production facility located in Branchburg, New Jersey, and is now entering full-scale contract manufacturing operations (CMO) for large-scale pharmaceuticals. With the completion of this U.S. production facility acquisition, Celltrion plans to secure a local production base in the United States to reduce tariff and supply chain risks while also launching its contract development and manufacturing organization (CDMO) business in earnest, which the company has identified as a mid-to-long-term growth engine.
Read the full article: Celltrion Acquires Eli Lilly’s U.S. Facility //
Source: https://www.businesskorea.co.kr/news/articleView.html?idxno=260120